Christian Schweiger
Founder at SHIELD THERAPEUTICS PLC
Net worth: 196 914 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hans-Peter Hasler | M | 68 | 6 years | |
| Karl Lundström | M | 62 | 3 years | |
| Jonas Hallén | M | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | 5 years |
| Jörg Klingelhöfer | M | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | 6 years |
| Lucy Huntington-Bailey | F | - | 9 years | |
| David Childs | M | - | 13 years | |
| Paul Spoors | M | - | 5 years | |
| Gregory Madison | M | 57 | 3 years | |
| Jackie Mitchell | M | - | 12 years | |
| Annette Koehler | M | 57 |
University of Duisburg-Essen
| 19 years |
| Peter Llewellyn-Davies | M | 66 | 8 years | |
| Maria Lacerca-Allen | M | 57 | 3 years | |
| Susanne Stuffers | M | 43 |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
| Santosh Shanbhag | M | 47 | - | |
| Karen Chandler Smith | F | - | - | |
| Birgitte Gangmark Villmo | F | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
| Volker Gruhn | M | 61 |
University of Duisburg-Essen
| - |
| Andy Hurley | M | - | 1 years | |
| Kari Grønås | F | 59 |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
| Dieter Schmitt | M | - |
University of Duisburg-Essen
| - |
| Joachim Wuermeling | M | 63 |
University of Duisburg-Essen
| 28 years |
| Till Neumann | M | - |
University of Duisburg-Essen
| - |
| Øystein Soug | M | 55 |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | 2 years |
| Robert Huber | M | 87 |
University of Duisburg-Essen
| - |
| Yuri Khodjamirian | M | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
| Tobias Kollmann | M | 54 |
University of Duisburg-Essen
| - |
| Bedrich Hosticka | M | - |
University of Duisburg-Essen
| 39 years |
| Farzad Abdi-Dezfuli | M | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Karis | M | 76 | 4 years | |
| Tim Watts | M | 66 | 3 years | |
| Carl Sterritt | M | 55 | 12 years | |
| Richard Jones | M | 58 | 7 years | |
| Joanne Elizabeth Estell | F | 53 | - | |
| Angela Hildreth | F | - | 6 years | |
| Rolf K. Hoffmann | M | 64 | 3 years | |
| Karl Keegan | M | 57 | 1 years | |
| Andrew Heath | M | 76 | 2 years | |
| Jose Menoyo | M | - | 2 years | |
| Mark Sampson | M | - | 5 years | |
| Karen Nugent | F | - | - | |
| Paul Steckler | M | - | - | |
| Kate Hopkinson | F | - | - | |
| Suzanne Wood | F | - | - | |
| Hans-Peter Rudolf | M | 58 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 28 | 63.64% |
| Norway | 8 | 18.18% |
| Germany | 8 | 18.18% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christian Schweiger
- Personal Network
